2Scotland GS, McNamee P, Philip Set al. Cost-effective- ness of implementing automated grading within the national screening programme for diabetic retinopathy in Scotland [J]. Br J Ophthalmol. 2007,91(11) : 1518-1523.
3Dewan V, Lambert D, Ecller J, et al. Cost-effective- ness analysis of ranibizumab plus prompt or deferred la- ser or trianlcinolone plus prompt laser for diabetic mac- ular edema [J]. Ophthalmology. 2012, 119 (8): 1679,1684.
4Mitchell P, Annemans L, Gallagher M, eta al. Cost-ef- fectiveness of ranibizumab in treatment of diabetic mac- ular oedema(DME) causing visual impairment: evidence from the RESTORE trial{J]. Br J Ophthalmol, 2012,96 (5):688-693.
5Javitt JC, Canner JK, Sommer A, Cost effectiveness of current approaches to the control of retinopathy in type 1 diabetics[J]. Ophthalmology. 1989,96(2):255-264.
6Aoki N,Dunn K, Fukui T, et al. Cost-effectiveness a- nalysis of telemedicine to evaluate diabetic retinopathy in a prison population[J]. Diabetes Care. 2004 May; 27 (5) : 1095-1101.
7Klonoff IX2, Schwartz DM. An economic analysis of in- terventions for diabetes [J]. Diabetes Care. 2000, 23 (3): 390-404.
